{{Drugbox
| verifiedrevid =  
| IUPAC_name = 5-(3-methylphenoxy)pyrimidin-2(1H)-one
| image = Tolimidone.svg
<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| excretion =  
<!--Identifiers-->
| CAS_number = 41964-07-2
| ATC_suffix =  
| PubChem = 39065
| DrugBank =  
| ChemSpiderID = 35751
| ChEMBL = 8030
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MU3JD8E9IS
| KEGG = D06182
| synonyms =  
<!--Chemical data-->
| C=11 | H=10 | N=2 | O=2
| molecular_weight = 202.21 g/mol
| smiles = O=C2/N=C\C(\Oc1cc(ccc1)C)=C/N2
}}
'''Tolimidone''' (CP-26154; MLR-1023) is a compound which was discovered by scientists at Pfizer, was found to stimulate secretion of [[gastric mucosa]], and was in development by Pfizer as a drug candidate to treat [[gastric ulcers]] but was abandoned.<ref name=SaporitoBook/><ref name=adis>{{cite web|title=Tolimidone|url=http://adisinsight.springer.com/drugs/800023467|publisher=AdisInsight|accessdate=26 August 2017|language=en}}</ref><ref>{{Cite journal|doi=10.1021/jm00183a012|title=Bronchodilator and antiulcer phenoxypyrimidinones|pmid=7411545|year=1980|last1=Lipinski|first1=C. A.|last2=Stam|first2=J. G.|last3=Pereira|first3=J. N.|last4=Ackerman|first4=N. R.|last5=Hess|first5=H. J.|journal=Journal of Medicinal Chemistry|volume=23|issue=9|pages=1026â€“31|quote=Compound 3 has been assigned the nonproprietary (USAN) name tolimidone}}</ref>  After the patent on the compound expired, scientists at the company Melior Discovery identified it as a potential drug candidate for diabetes through a [[phenotypic screen]] and as of 2016 Melior was [[drug repurposing|repurposing]] it for diabetes.<ref name=SaporitoBook>{{cite book|last1=Saporito|first1=Michael S.|last2=Lipinski|first2=Christopher A.|last3=Reaume|first3=Andrew G.|editor1-last=Barratt|editor1-first=Michael J.|editor2-last=Frail|editor2-first=Donald E.|title=Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs|date=2012|publisher=John Wiley & Sons|isbn=9781118274392|page=270|url=https://books.google.com/?id=TqOBrx_xZgAC&pg=PA270|language=en|chapter=Chapter 9:Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates}}</ref><ref name=adis/>

==References==
{{reflist}}


{{H2-receptor antagonist}}

[[Category:Bronchodilators| ]]
[[Category:Pyrimidines]]
[[Category:Ureas]]
[[Category:Lactams]]
[[Category:Phenol ethers]]